Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
261studies shown
Showing 205-216 of 261
Drug study icon
TerminatedNCT01121536

Safety and Efficacy of Armodafinil Treatment for depression

This study was terminated in the United States, in Australia, in France, .... It is testing safety and Efficacy of Armodafinil Treatment for depression.

In France
Why is this study shown?

This study includes Depression among several conditions.

Bipolarity, DepressionDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
United States, Australia, France, ...
Sponsor
Cephalon
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT04133233

Low Dose IL-2 Therapy in people with a Depressive Episode in the Course of a Bipolarity

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand whether a therapy or guided support program can better prevent setbacks and support longer-term stability.

In France
Why is this study shown?

This study includes Depression among several conditions.

Bipolarity, DepressionDrugFrom 18 Years to 65 Years
Countries
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT01072630

Armodafinil Treatment for depression

This study is completed in the United States, in Australia, in France, .... It is testing armodafinil Treatment for depression.

In France
Why is this study shown?

This study includes Depression among several conditions.

Bipolarity, DepressionDrugFrom 18 Years to 65 Years
Countries
United States, Australia, France, ...
Sponsor
Cephalon
Condition
Bipolarity, Depression
Device study icon
CompletedNCT01644747

tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients

This study exists to see whether a therapy or guided support program can make care clearer and more responsive. Researchers are trying to understand whether a therapy or guided support program can give earlier or clearer feedback during care.

In France
Why is this study shown?

This study includes Depression among several conditions.

Bipolarity, DepressionDeviceA study involving a tool, app, wearable, test, or medical device.From 18 Years to 65 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Besancon
Condition
Bipolarity, Depression
Device study icon
Active Not RecruitingNCT07057024

Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression

This observational study is following people with mental health conditions to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.

Remote / online
Why is this study shown?

This study includes Depression among several conditions.

Bipolarity, Depression, ...OtherFrom 18 Years to 60 Years
Countries
France
Sponsor
Etablissement Public de Santé Barthélemy Durand
Condition
Bipolarity, Depression, ...
Behavioral study icon
CompletedNCT04570202

Health cAre woRkers exposeD to COVID-19

This summary needs review. Please check the official study record and contact the research team for details.

In France
Why is this study shown?

This study includes Depression among several conditions.

PTSD, DepressionBehavioralOver 18 Years
Countries
France
Sponsor
University Hospital, Tours
Condition
PTSD, Depression
Behavioral study icon
CompletedNCT04916275

Post-traumatic Stress, Signs of Depression and Burnout Syndrome Among Nursing Home Staff in Occitanie During the COVID-19 Pandemic

This study exists to explore whether the medication COVID-19 could improve care and understanding. Researchers are trying to understand what the medication COVID-19 could change in day-to-day care and decision-making.

In France
Why is this study shown?

This study includes Depression among several conditions.

Addiction, Depression, ...BehavioralOver 18 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Nīmes
Condition
Addiction, Depression, ...
Drug study icon
CompletedNCT00868959

Lurasidone - A 24-week Extension Study of people with Bipolar I Depression

This study exists to explore whether the medication Patients could improve care and understanding. For people living with Bipolarity, that matters because care needs to work in daily life, not just in theory.

In France
Why is this study shown?

This study includes Depression among several conditions.

Bipolarity, DepressionDrugFrom 18 Years to 75 Years
Countries
United States, France, Canada, ...
Sponsor
Sumitomo Pharma America, Inc.
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT00868452

Lurasidone - A 6-week Study of people with Bipolar I Depression (Add-on)

This study exists to explore whether the medication Patients could improve care and understanding. Researchers are trying to understand what the medication Patients could change in day-to-day care and decision-making.

In France
Why is this study shown?

This study includes Depression among several conditions.

Bipolarity, DepressionDrugFrom 18 Years to 75 Years
Countries
United States, France, Czechia, ...
Sponsor
Sumitomo Pharma America, Inc.
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT00868699

Lurasidone - A 6-week Study of people with Bipolar I Depression (Monotherapy)

This study exists to explore whether the medication Patients could improve care and understanding. For people living with Bipolarity, that matters because care needs to work in daily life, not just in theory.

In France
Why is this study shown?

This study includes Depression among several conditions.

Bipolarity, DepressionDrugFrom 18 Years to 75 Years
Countries
United States, France, Czechia, ...
Sponsor
Sumitomo Pharma America, Inc.
Condition
Bipolarity, Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.